Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The company's cash runway has been extended into the first quarter of 2026. ABUS is reducing its workforce by 24% as a result of recent pipeline optimization. Multiple data presentations are upcoming ...